In patients with metastatic melanoma, known to be a high heterogenic responding tumor, PD-1 immunohistochemistry staining on biopsies was not a good predictor of response to ICI and hence is not used in clinical practice (12). The gene discussed is PDCD1; the disease is neoplasm.